PD‐L1 and CD47 co‐expression predicts survival and enlightens future dual‐targeting immunotherapy in non‐small cell lung cancer
Abstract Backgroud Recent studies have indicated that programmed cell death‐ligand 1 (PD‐L1) and cluster of differentiation 47 (CD47) play an essential role in tumor immune evasion and may serve as potential targets for combined immunotherapy. The aim of our study was to evaluate the PD‐L1/CD47 expr...
Main Authors: | Zhenlin Yang, Yue Peng, Wei Guo, Jiachen Xu, Lin Li, He Tian, Renda Li, Lei Liu, Fengwei Tan, Shugeng Gao, Jie He |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2021-06-01
|
Series: | Thoracic Cancer |
Subjects: | |
Online Access: | https://doi.org/10.1111/1759-7714.13989 |
Similar Items
-
Research Progress on Relation Between CD47 and Immunotherapy on Lymphoma
by: LUO Yiyang, et al.
Published: (2021-08-01) -
Potential New Cancer Immunotherapy: Anti-CD47-SIRPα Antibodies
by: Lu Q, et al.
Published: (2020-09-01) -
A Novel Blockade CD47 Antibody With Therapeutic Potential for Cancer
by: Fangzhen Lin, et al.
Published: (2021-01-01) -
Role of CD47 in Hematological Malignancies
by: Entsar Eladl, et al.
Published: (2020-07-01) -
Characterization of the Pathophysiological Role of CD47 in Uveal Melanoma
by: Maria Cristina Petralia, et al.
Published: (2019-07-01)